4//SEC Filing
FAVUS ELLIOT 4
Accession 0001731122-21-000308
CIK 0001314052other
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 9:31 PM ET
Size
12.0 KB
Accession
0001731122-21-000308
Insider Transaction Report
Form 4
FAVUS ELLIOT
Director
Transactions
- Exercise/Conversion
Common Stock
2021-02-24$2.58/sh+45,500$117,390→ 45,000 total - Exercise/Conversion
Common Stock
2021-02-24$3.28/sh+100,000$328,000→ 145,000 total - Sale
Common Stock
2021-02-24$12.66/sh−145,500$1,841,855→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-24−45,500→ 0 totalExercise: $2.58Exp: 2028-10-01→ Common Stock (45,500 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-24−100,000→ 0 totalExercise: $3.28From: 2016-09-22Exp: 2026-09-22→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]The options vested upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials.
Documents
Issuer
ANAVEX LIFE SCIENCES CORP.
CIK 0001314052
Entity typeother
Related Parties
1- filerCIK 0001608022
Filing Metadata
- Form type
- 4
- Filed
- Feb 25, 7:00 PM ET
- Accepted
- Feb 26, 9:31 PM ET
- Size
- 12.0 KB